Pax‐8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens

“…[17][18][19] Several studies, each of which is devoted exclusively to either PAX2 or PAX8, have documented their expression in ovarian tumors. 11,[20][21][22][23] These studies further suggest a similar pattern of expression for PAX2 and PAX8 in these ovarian tumors. Nevertheless, a comprehensive direct combination of these 2 markers is not available, leaving several pertinent diagnostic issues unresolved, such as their comparative diagnostic sensitivity and specificity in ovarian serous tumors and ovarian mucinous tumors.…”

mentioning

confidence: 87%

PAX2 and PAX8 Reliably Distinguishes Ovarian Serous Tumors From Mucinous Tumors

Wang

Pan

et al. 2015

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of cancer-related death in gynecologic malignancies and consists of different histologic types. Histopathologic examination and accurate subtype diagnosis has become increasingly important in guiding patient management and, as such, is the most important currently available ovarian carcinoma "biomarker." In this study, we examined the expression of PAX2 and PAX8 by immunohistochemistry in 58 cases of ovarian serous tumors and 68 cases of ovarian mucinous tumors. The results demonstrated that PAX2 and PAX8 were detected in 100% (30/30) and 77% (23/30) of serous cystadenomas, 100% (16/16) and 94% (15/16) of borderline serous cystadenomas, and 100% (12/12) and 83% (10/12) of serous carcinomas, respectively. However, PAX2 and PAX8 were detected in only 0% (0/29) and 0% (0/29) of mucinous cystadenoma, 4% (1/24) and 4% (1/24) of borderline mucinous cystadenoma, and 0% (0/15) and 7% (1/15) of mucinous carcinoma, respectively. Further, there is a linear correlation between PAX2 and PAX8 (R=0.745; P<0.0001). Overall, our data indicated that PAX2 correlated with PAX8, and these 2 proteins differentially expressed in ovarian serous tumors and ovarian mucinous tumors. Thus, PAX2 and PAX8 are useful biomarker in the differential diagnosis of ovarian serous and mucinous tumors.

show abstract

“…However, their reactivity is often complex and they should be used as an integral part of a panel ( Table 2 ) [ 7 ]. The most classical antibodies with complex reactivity, used when dealing with a CUP CK7+/CK20− are: TTF1, GATA3, PAX8 and WT1 [ 13 ].…”

Section: Diagnostic Workflow Of Ck7+/ck20− Cupsmentioning

confidence: 99%

Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site

Sèlves

Long‐Mira

Mathieu

et al. 2018

Cancers

154

108

View full text Add to dashboard Cite

Immunohistochemistry has become an essential ancillary examination for the identification and classification of carcinomas of unknown primary site (CUPs). Over the last decade, the diagnostic accuracy of organ- or tumour-specific immunomarkers and the clinical validation of effective immunohistochemical panels has improved significantly. When dealing with small sample sizes, diagnostic accuracy is crucial, particularly in the current era of targeted molecular and immune-based therapies. Effective systematic use of appropriate immunohistochemical panels enables accurate classification of most of the undifferentiated carcinomas as well as careful preservation of tissues for potential molecular or other ancillary tests. This review discusses the algorithmic approach to the diagnosis of CUPs using CK7 and CK20 staining patterns. It outlines the most frequently used tissue-specific antibodies, provides some pitfalls essential in avoiding potential diagnostic errors and discusses the complementary tools, such as molecular tumour profiling and mutation-specific antibodies, for the improvement of diagnosis and prediction of the treatment response.

show abstract

Pax‐8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens

Cited by 10 publications

References 6 publications

Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma

Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma

PAX2 and PAX8 Reliably Distinguishes Ovarian Serous Tumors From Mucinous Tumors

Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site

Contact Info

Product

Resources

About